Shionogi & Co., Ltd. (OTCMKTS:SGIOY – Get Free Report) reached a new 52-week high during trading on Tuesday . The company traded as high as $11.10 and last traded at $10.77, with a volume of 41881 shares. The stock had previously closed at $7.19.
Shionogi & Co., Ltd. Stock Up 49.7 %
The company has a current ratio of 5.86, a quick ratio of 5.37 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $11.06 and its two-hundred day moving average is $11.14. The company has a market capitalization of $12.78 billion, a PE ratio of 12.64, a P/E/G ratio of 2.37 and a beta of 0.23.
Shionogi & Co., Ltd. (OTCMKTS:SGIOY – Get Free Report) last announced its earnings results on Monday, July 29th. The company reported $0.17 earnings per share for the quarter. The business had revenue of $625.99 million for the quarter. Shionogi & Co., Ltd. had a return on equity of 11.95% and a net margin of 35.53%. As a group, analysts predict that Shionogi & Co., Ltd. will post 0.96 EPS for the current year.
About Shionogi & Co., Ltd.
Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
Recommended Stories
- Five stocks we like better than Shionogi & Co., Ltd.
- How to Capture the Benefits of Dividend Increases
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Best Aerospace Stocks Investing
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Shionogi & Co. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.